{"id":496569,"date":"2020-07-16T18:02:01","date_gmt":"2020-07-16T18:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496569"},"modified":"2020-07-16T18:02:01","modified_gmt":"2020-07-16T18:02:01","slug":"cancer-cachexia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-cachexia-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_496569.html","title":{"rendered":"Cancer Cachexia Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"Cancer<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Cancer Cachexia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

Cancer cachexia is a wasting syndrome, which is characterized by weight loss, anorexia (loss of desire to eat), asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors. It occurs in patients with advanced cancer, chronic obstructive pulmonary disease, chronic infection including AIDS and tuberculosis, chronic heart failure, and rheumatoid arthritis. However, the occurrence of cancer cachexia is high, especially in patients with advanced cancer, this syndrome often remains underdiagnosed.<\/em><\/p>\n

Multiple abnormalities in protein, fat, and carbohydrate metabolism as well as peripheral hormone and neuropeptide metabolism have been reported as the cause of cancer cachexia. Investigations in humans suggest a central role of tumor\u2010induced inflammation as the primary cause of cachexia development.<\/span><\/em><\/p>\n

 <\/span><\/p>\n

Get FREE sample copy at: <\/span><\/strong><\/p>\n

 https:\/\/www.delveinsight.com\/sample-request\/Cancer-cachexia-CC-market-insights%20<\/a><\/strong><\/p>\n

  <\/p>\n

\"Cancer-Cachexia-Market-Size-and-Share\"<\/p>\n

<\/span><\/span><\/strong><\/p>\n

The Cancer Cachexia market report also covers emerging drugs, current treatment practices, <\/strong><\/span>Cancer Cachexia market share of the individual therapies, current and forecasted Cancer Cachexia Market Size<\/span> from 2017 to 2030 segmented by seven major markets. <\/span><\/p>\n

The report provides a detailed current Cancer Cachexia treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/span><\/p>\n

 <\/span><\/span><\/p>\n

Cancer Cachexia Market Key Facts<\/span><\/strong><\/p>\n

 As per a Japanese study conducted by Aoyagi et al. “Cancer cachexia, mechanism and treatment”, cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients.<\/em><\/p>\n

Several secondary studies suggest that the overall incidence of cachexia is high and in industrialized countries, such as, North America, Europe, Japan it is growing. It is currently estimated that cachexia affects approximately 9 million patients, which is about 1% of all patients with any disease.<\/em><\/p>\n

It is estimated that more than 30% of cancer  patients die due to cachexia, and more than  50% of patients die with cachexia being present.<\/em><\/p>\n

 <\/span><\/p>\n

 Key Benefits of Cancer Cachexia Market Report<\/span><\/strong><\/p>\n